Loading…
Trevi Therapeutics, Inc. is projected to rise to $23.58 by 2027, a +28% move from its current price of $18.40. TRVI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $17.69 | $18.41 | $19.16 | +0.05% |
| Aug 2 | $17.41 | $18.42 | $19.49 | +0.10% |
| Aug 3 | $17.20 | $18.43 | $19.75 | +0.15% |
| Aug 4 | $17.02 | $18.44 | $19.97 | +0.19% |
| Aug 5 | $16.87 | $18.44 | $20.17 | +0.24% |
| Aug 6 | $16.73 | $18.45 | $20.35 | +0.29% |
| Aug 7 | $16.61 | $18.46 | $20.52 | +0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.61 | $18.46 | $20.52 | +0.34% |
| Week 2 | $15.95 | $18.52 | $21.51 | +0.68% |
| Week 3 | $15.48 | $18.59 | $22.32 | +1.02% |
| Week 4 | $15.10 | $18.65 | $23.04 | +1.36% |
| Week 5 | $14.78 | $18.71 | $23.70 | +1.71% |
| Week 6 | $14.50 | $18.78 | $24.32 | +2.05% |
| Week 7 | $14.25 | $18.84 | $24.91 | +2.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc.
was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Trevi Therapeutics, Inc. (TRVI) is in the Healthcare sector and currently trades with a price of $18.18 and a market capitalization of $2.58B. The stock is ranked 1864 by market cap.
The asset sits in the healthcare space and is developing nalbuphine-based therapies for chronic cough associated with IPF and other interstitial lung diseases. The near-term price outlook shows a path of growth supported by a mid-range price trajectory from the current level toward higher targets over time.
A major floor 42.2% below — a decisive break under it would weaken the trend.
The nearest floor, 11.0% below — buyers have tended to step in here.
The nearest ceiling, 6.0% above — a clean break opens room to run.
A major ceiling 15.3% above — clearing it would confirm fresh momentum.
Key TRVI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TRVI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.12 | Buy | $18.14 | Buy |
| MA 10 | $17.91 | Buy | $17.99 | Buy |
| MA 20 | $17.96 | Buy | $17.75 | Buy |
| MA 50 | $16.31 | Buy | $16.66 | Buy |
| MA 100 | $14.70 | Buy | $15.22 | Buy |
| MA 200 | $13.12 | Buy | $13.24 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.23 | Neutral |
| Stoch RSI (14) | 56.73 | Neutral |
| CCI (20) | 55.00 | Neutral |
| Williams %R (14) | -26.27 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | 2.74 | Buy |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 73.73 | Neutral |
| TRIX (15) | 0.42 | Buy |
| Awesome (5,34) | 0.64 | Buy |
| Ultimate (7,14,28) | 53.28 | Neutral |
| Momentum (10) | 1.04 | Buy |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 18.46 | Sell |
| ADX (14) | 16.28 | Neutral |
| ATR (14) | 0.66 | Info |
Near-term technical picture shows a bullish tilt. The RSI14 is 50, and the 50-day simple moving average is $15.85 while the 200-day simple moving average is $12.83. Supports and resistances are noted at $13.40 and $19.50 respectively, framing a 30-day range from $13.32 to $24.82.
The stock exhibits high volatility, with annualized volatility at 90%. This combination suggests potential for movement within the 30-day window, with upside resistance near $19.50 and downside support near $13.40.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.99 | $18.40 | $26.68 | 0% | Neutral | |
| $18.02 | $23.58 | $33.07 | +28% | Bullish | |
| $20.62 | $28.18 | $41.62 | +53% | Bullish | |
| $21.22 | $30.09 | $46.22 | +64% | Bullish | |
| $27.64 | $40.48 | $64.27 | +120% | Bullish | |
| $36.43 | $54.97 | $89.80 | +199% | Bullish | |
| $38.47 | $59.69 | $100.02 | +224% | Bullish | |
| $45.90 | $73.15 | $125.39 | +298% | Bullish | |
| $46.09 | $75.34 | $131.87 | +309% | Bullish | |
| $42.85 | $71.79 | $128.11 | +290% | Bullish | |
| $73.58 | $138.30 | $267.29 | +652% | Bullish | |
| $172.71 | $383.79 | $831.06 | +19.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.99 | $18.40 | $21.51 | +0.00% |
| August 2026 | $15.47 | $18.33 | $22.37 | -0.36% |
| September 2026 | $16.03 | $19.23 | $23.91 | +4.88% |
| October 2026 | $16.98 | $20.57 | $25.97 | +6.99% |
| November 2026 | $16.96 | $20.72 | $26.48 | +0.72% |
| December 2026 | $16.78 | $20.65 | $26.68 | -0.32% |
Click any year to see its month-by-month TRVI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TRVI is projected to trade between $9.99 and $26.68, averaging $18.40 — a potential gain of 0% from today's $18.40. Price action looks broadly range-bound.
Trevi Therapeutics, Inc.'s 2027 outlook centres on $23.58, within a $18.02 to $33.07 range. That is up +28% on the projected 2026 average. That marks a +28% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, TRVI could reach as high as $41.62, with a base case around $28.18 and support toward $20.62 — roughly +53% from $18.40. Momentum favours further upside here.
Expect TRVI to range from $21.22 to $46.22 through 2029. The $30.09 average target implies a +64% move from current prices. That is up +7% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The TRVI price prediction for 2030 points to an average of $40.48 (low $27.64, high $64.27) — a potential gain of +120% on today's $18.40. Momentum favours further upside here.
In 2031, TRVI is projected to trade between $36.43 and $89.80, averaging $54.97 — a potential gain of +199% from today's $18.40. That is up +36% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Trevi Therapeutics, Inc.'s 2032 outlook centres on $59.69, within a $38.47 to $100.02 range. That is up +9% on the projected 2031 average. That marks a +224% change versus current levels. Momentum favours further upside here.
By 2033, TRVI could reach as high as $125.39, with a base case around $73.15 and support toward $45.90 — roughly +298% from $18.40. Buyers look set to stay in control over this stretch.
Expect TRVI to range from $46.09 to $131.87 through 2034. The $75.34 average target implies a +309% move from current prices. That is up +3% on the projected 2033 average. Momentum favours further upside here.
The TRVI price prediction for 2035 points to an average of $71.79 (low $42.85, high $128.11) — a potential gain of +290% on today's $18.40. Buyers look set to stay in control over this stretch.
In 2040, TRVI is projected to trade between $73.58 and $267.29, averaging $138.30 — a potential gain of +652% from today's $18.40. That is up +93% on the projected 2035 average. Momentum favours further upside here.
Trevi Therapeutics, Inc.'s 2050 outlook centres on $383.79, within a $172.71 to $831.06 range. That is up +177% on the projected 2040 average. That marks a +19.9x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in TRVI today (≈ 54.347826 TRVI) could be worth
$20,858.31
+$19,858.31 (+1986%) by 2050 · US Dollar
Based on the average projected TRVI price of $383.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TRVIwould be worth at today's price.
$1,000 invested in TRVI on Jul 30, 2025 (≈ 134.770888 TRVI) would be worth
$2,479.78
+$1,479.78 (+148.0%) today · 2.48× · US Dollar
Based on a TRVI entry price of $7.42 vs. today's $18.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.18 | $1,071.01 | +7.1% |
| 1 month ago | $18.65 | $986.6 | -1.3% |
| 3 months ago | $13.87 | $1,326.6 | +32.7% |
| 6 months ago | $10.47 | $1,757.4 | +75.7% |
| 1 year ago | $7.42 | $2,479.78 | +148.0% |
| All time (5.0y) ago | $1.98 | $9,292.93 | +829.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TRVI forecast.
Our base-case forecast reaches $37.00 around 2030.
Implied market cap at $37.00: $5.25B
The multi-year forecast paints a clear long-run growth path with rising averages and sizable ROIs. In 2026 the forecasted average price is $18.18 with a min of $9.99 and a max of $27.36, ROI of 0, and a Neutral sentiment. By 2027 the average is $23.26 (min $17.29, max $33.71) with ROI 27.9 and bullish sentiment, followed by 2028 at an average of $27.19 (min $19.18, max $41.77) and ROI 49.6, bullish.
The 2029 forecast shows an average of $29.02 (min $19.58, max $46.62) with ROI 59.6 and bullish sentiment. In 2030 the average rises to $39.02 (min $25.29, max $65.05) with ROI 114.6 and bullish sentiment. The outlook continues to strengthen through 2035 with 2031: avg $53.56, min $33.45, max $92.20, ROI 194.6; 2032: avg $59.34, min $35.77, max $105.07, ROI 226.4; 2033: avg $73.06, min $42.58, max $132.70, ROI 301.9; 2034: avg $72.14, min $40.70, max $134.11, ROI 296.8; 2035: avg $67.37, min $36.82, max $127.95, ROI 270.6, all with bullish sentiment.
The momentum extends to 2040 with average $130.87 (min $61.51, max $271.46) and ROI 619.9, and to 2050 with average $382.72 (min $172.23, max $880.26) and ROI 2005.2, continuing a bullish stance across the horizon.
Tap a question to reveal the answer.
In 2030, the forecast shows min $25.29, avg $39.02, max $65.05, with ROI 114.6 and a bullish sentiment.
The longer-term outlook is bullish, with rising averages and high ROIs from 2027 onward (e.g., 2027 avg $23.26, ROI 27.9; 2031 avg $53.56, ROI 194.6). Near term, 2026 shows avg $18.18 with ROI 0 and neutral sentiment, while volatility remains high at 90%.
Yes. The forecast shows 2032 max $105.07 and 2033 max $132.70, with higher tops later (2040 max $271.46 and 2050 max $880.26), indicating potential above $100 in the horizon.
Current price is $18.18 and market cap is $2.58B.
TRVI is categorized in Healthcare.
Trevi Therapeutics, Inc. Community Discussion
0Share your Trevi Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.